Optum Rx standard formularies currently include the weight loss drugs Wegovy and Saxenda, and the PBM is evaluating Zepbound.
Beginning Jan. 1, 2024, Optum Rx will begin offering plan sponsors a new weight management and wellness support program. Called Optum Rx Weight Engage, the program is designed to support employers, health plans and the consumers and provide better health outcomes.
Optum Rx’s program will support the consumer with navigation through their specific benefit coverage, with a specialized provider network and coaching and lifestyle programs. Clients have the flexibility to configure elements that best fit their and their consumers’ needs. Consumers can access coaching either in person or through a digital platform.
U.S. prevalence of obesity increased from 30.5% during the period 1999 to 2000 to 41.9% during the 2017 to March 2020, according to the CDC. Obesity-related conditions, such as heart disease, stroke, type 2 diabetes and certain types of cancer, are among the leading causes of preventable death. Drugs such as Wegovy (semaglutide), Saxenda (liraglutide) and the newest weight loss drug Zepbound (tirzepatide) activate receptors of hormones secreted from the intestine — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — to reduce appetite and food intake.
Optum Rx standard formularies include Wegovy and Saxenda, and a spokesperson said Optum Rx is evaluating Zepbound. Express Scripts and Cigna recently announced they would add Zepbound to their formularies.
Related: Younger People Are Looking to GLP-1 Drugs for Weight Loss
Also beginning in January 2024, Optum Rx will shift eight insulin products, including all short- and rapid-acting insulins, to tier one, or “preferred” status, on standard formularies. Three manufacturers will have products added to tier one, including Eli Lilly, Novo Nordisk and Sanofi. As a result, 98% of all Optum Rx consumers will have access to insulin for $35 or less per month.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More